Entering text into the input field will update the search result below

Dosing underway in study of Momenta's engineered immunoglobulin G

Jan. 29, 2019 11:39 AM ETMomenta Pharmaceuticals, Inc. (MNTA) StockBy: Douglas W. House, SA News Editor
  • The first patient has been dosed in a Phase 1/2 clinical trial evaluating Momenta Pharmaceuticals' (NASDAQ:MNTA) M254 in healthy volunteers and in patients with immune thrombocytopenic purpura, an autoimmune disorder characterized by low blood platelets and excessive bruising and bleeding.
  • The company says M254 is a hyper-sialylated immunoglobulin G engineered from pooled plasma that is more than 10 times as potent as conventional intravenous IgG.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
MNTA--
Momenta Pharmaceuticals, Inc.